TrialBMC infectious diseases2023

Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.

Fatemeh Gholami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.